Global Cell Therapy Manufacturing Market Overview
Cell Therapy Manufacturing Market was valued at US$ 4.7 Billion in 2024 and is projected to grow at a CAGR of 13.90% to reach US$ 17.3 Billion by 2034.
Cell therapy includes replacing diseased or damaged cells with new, healthy ones, altering the function of the patient's cells by the production of factors or direct interaction, and utilizing immune cells to remove disease-causing or malfunctioning cells. Cell therapies are used to treat conditions such as cancer, autoimmune illness, urine issues, infectious diseases, repair spinal cord injuries, and treat patients with neurological diseases.
The high prevalence of cancer and other target diseases and increasing R&D investments in pharmaceutical companies have become key factors in the growth of the Cell Therapy Manufacturing Market. Rising incidence of chronic and infectious diseases and the rise in large number of oncology-related cell therapy clinical trials has given rise to demand for the target market. The rising approval of GMP certifications for cell therapy production facilities, continuous technological advancements in the field of cell therapy has also become the major contribution in the growth of Cell Therapy Manufacturing Market.
Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.
Global Cell Therapy Manufacturing Market Dynamics
Increasing inclination of physicians towards the therapeutic use of allogeneic therapies to fuel market growth
Allogeneic cells have advantages because they generate immune stem cells that eradicates cancer cells that persist even after high-dose of cytotoxic chemical treatment. Since allogeneic therapies comes from healthy sources, there are more functional cells available. Additionally, allogeneic techniques enable the creation of several medicines, thus allogeneic therapies have become the major factor in the growth of the Cell Therapy Manufacturing Market. The cost of an allogeneic therapy is significantly lower compared to autologous therapies that in turn have driven the growth of Cell Therapy Manufacturing Market.
For instance, in October 2020, The University of Texas MD Anderson Cancer Center and Allogene Therapeutics, Inc., a clinical stage biotechnology company leading the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products announced a strategic five-year collaboration agreement for the preclinical and clinical investigation of AlloCAR T candidates across Allogene’s broad portfolio of hematologic and solid tumors. Under the agreement, MD Anderson and Allogene collaborated on the design and conduct preclinical and clinical studies with oversight from a joint steering committee, provided by the funding, developmental candidates, and other support.
Increasing Private and Government investments in cell therapy industry
Companies that offer cell therapies are drawing more private and governmental funding despite the relatively few approvals. Over the forecast period, private equity and capital investments in the life sciences have risen sharply. Therefore, investments in cell therapy industries have the major contribution in the growth of the Cell Therapy Manufacturing Market.
For instance, in January 2022, Century Therapeutics, an innovative biotechnology company developing transformative allogeneic cell therapies and Bristol Myers Squibb, a company that aims to manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease announced a collaboration and license agreement to develop and commercialize two program, four induced pluripotent stem cell and engineered natural killer cell or T cell for hematologic malignancies and solid tumors.
Restrains:
Due to the intricate nature of the cells and treatment logistics, the current technologies have limited production numbers and the large number of manual manipulations involved with current methods due to which cell therapies are very expensive to produce, which in turn restrain the growth of Cell Therapy Manufacturing Market.
Furthermore, in May 2022, the Food and Drug Administration (FDA) approved “brexucabtagene autoleucel” introduced by Tecartus and Kite Pharma, Inc. The brexucabtagene autoleucel is a CD19-directed chimeric antigen receptor (CAR) T-cell therapy used in adults for relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). It costs around US$ 475,000 for a single intrusion which result in limited adoption of chimeric antigen receptor (CAR) T-cell therapy, thereby hampering the growth of Cell Therapy Manufacturing Market.
Global Cell Therapy Manufacturing Market Segmentation
Cell Therapy Manufacturing Market is segmented based on Therapy Type, Technology, Source, Application and Region.
Therapy Type Insight
On the basis of Therapy Type, Cell Therapy Manufacturing Market is segmented into Allogeneic Cell Therapy and Autologous Cell Therapy. Allogeneic Cell Therapy type segment is expected to dominate the target market growth as it is cheaper, more easily automated and is available as a scalable “off-the-shelf” product. It reduces dependence on patient T-cells which in turn boost the segment growth.
Technology Insights
On the basis of Technology, Cell Therapy Manufacturing Market is segmented into Somatic Cell Technology, Cell Immortalization Technology, Viral Vector Technology, Genome Editing Technology, Cell Plasticity Technology, and 3D Technology. Viral Vector Technology segment, are expected to dominate the target market growth due to their ability to protect transgenes from biological degradation and the capability to efficiently cross cellular barriers.
Source Insights
On the basis of Source, Cell Therapy Manufacturing Market is segmented into IPSC’s, Bone Marrow, Umbilical Cord, Adipose Tissue, and Neural Stem Cells. IPSC’s (induced pluripotent stem cells) segment are expected to dominate the target market growth as they are easily accessible, expandable and has the ability to give rise to almost any desired cell types. It has the potential to develop personalized medicine using patient-specific iPSCs.
Application Insights
On the basis of Application, Cell Therapy Manufacturing Market is segmented into Musculoskeletal, Cardiovascular, Gastrointestinal, Neurological, Oncology, Dermatology, and Other. The Cardiovascular segment is expected to dominate the target market growth due to rising prevalence of cardiovascular disease around the world and the limited therapeutic options for severe heart failure. There is a desperate need for new technology that can use the heart's ability to regenerate it which in turn propel the demand for cell therapy and fueling the growth of Cell Therapy Manufacturing Market.
Regional Insights:
On the basis of region, the Cell Therapy Manufacturing Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America market is estimated to witness a significantly high revenue share over the forecast period, owing to factors such as growing engagement of entities in research and product development in gene and cell therapy. Increase in substantial number of contract development organizations, expansion of manufacturing facilities by homegrown companies are anticipated to increase demand for Cell Therapy Manufacturing in the region.
|
Attribute |
Details |
|
Base year for estimation |
2023 |
|
Forecast period |
2024 – 2034 |
|
Market representation |
Revenue in USD Billion & CAGR from 2024 to 2034 |
|
Market Segmentation |
By Therapy Type - Allogeneic Cell Therapy and Autologous Cell Therapy By Technology - Somatic Cell Technology, Cell Immortalization Technology, Viral Vector Technology, Genome Editing Technology, Cell Plasticity Technology, and 3D Technology By Source - IPSC’s, Bone Marrow, Umbilical Cord, Adipose Tissue, and Neural Stem Cells By Application - Musculoskeletal, Cardiovascular, Gastrointestinal, Neurological, Oncology, Dermatology, and Other |
|
Regional scope |
North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa |
|
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segments Covered in the Report:
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2022 to 2032. For the purpose of this study, has segmented the Cell Therapy Manufacturing Market report based on Therapy Type, Technology, Source, Application and Region:
Cell Therapy Manufacturing Market, By Therapy Type:
- Allogeneic Cell Therapy
- Autologous Cell Therapy
Cell Therapy Manufacturing Market, By Technology:
- Somatic Cell Technology
- Cell Immortalization Technology
- Viral Vector Technology
- Genome Editing Technology
- Cell Plasticity Technology
- 3D Technology
Cell Therapy Manufacturing Market, By Source:
- IPSC’s
- Bone Marrow
- Umbilical Cord
- Adipose Tissue
- Neural Stem Cells
Cell Therapy Manufacturing Market, By Application:
- Musculoskeletal
- Cardiovascular
- Gastrointestinal
- Neurological
- Oncology
- Dermatology
- Other
Cell Therapy Manufacturing Market, By Region:
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
Global Cell Therapy Manufacturing Market Key Players
The key players operating the Cell Therapy Manufacturing Market includes, Pharmicell Co. Ltd., Merck Group, Thermo Fisher Scientific Inc., Lonza Group, Miltenyi Biotec GmBH, Takara Bio Group, STEMCELL Technologies, Cellular Dynamics International, Becton Dickinson & Company, Bio-Rad Laboratories, Inc., and others.
Global Cell Therapy Manufacturing Market Key Issues Addressed
Recent Development:
- In January 2023, “Curate Biosciences” launched new Curate Cell Processing System, its first product, to revolutionize cell therapy manufacturing prices and performance. Better starting materials for CAR-T cancer therapies and other cell therapies are produced using the ground-breaking Curate System. From patient-sourced leukapheresis blood product, its remarkably delicate microfluidic technique recovers around 90% of white blood cells while eliminating more than 90% of red cells and 99% of platelets, producing cells that allow improved transduction efficiency for therapeutic manufacture.
- In January 2023, Catalent launched new case management service for end-to-end supply chain case management of cell and gene therapies. This service has been specifically designed to address the special challenges associated with the safe and timely delivery of advanced therapies to patients by providing professional supply chain oversight from program start to finish.
Global Cell Therapy Manufacturing Market Company Profile
- Pharmicell Co. Ltd.*
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Merck Group
- Thermo Fisher Scientific Inc.
- Lonza Group
- Miltenyi Biotec GmBH
- Takara Bio Group
- STEMCELL Technologies
- Cellular Dynamics International
- Becton Dickinson & Company
- Bio-Rad Laboratories, Inc.
“*” marked represents similar segmentation in other categories in the respective sectio
Global Cell Therapy Manufacturing Market Table of Contents
- Research Objective and Assumption
- Preface
- Research Objectives
- Study Scope
- Years Considered for the study
- Assumptions
- Abbreviations
- Research Methodology
- Research data
- Primary Data
- Primary Interviews
- Primary Breakdown
- Key data from Primary Sources
- Key Thickness Insights
- Secondary Data
- Major Secondary Sources
- Secondary Sources
- Market Estimation
- Top-Down Approach
- Approach for estimating Market Share by Top-Down Analysis (Supply Side)
- Bottom-Up Approach
- Approach for estimating market share by Bottom-up Analysis (Demand Side)
- Market Breakdown and Data Triangulation
- Research Assumptions
- Market Preview
- Executive Summary
- Key Findings—Global Outlook for medical carts Strategies
- Key Questions this Study will Answer
- Market Snippet, By Therapy Type
- Market Snippet, By Technology
- Market Snippet, By Source
- Market Snippet, By Application
- Market Snippet, By Region
- Opportunity Map Analysis
- Executive Summary—3 Big Predictions
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restrains
- Market Opportunities
- Market Trends
- DR Impact Analysis
- PEST Analysis
- Porter’s Five Forces Analysis
- Opportunity Orbit
- Market Investment Feasibility Index
- Macroeconomic Factor Analysis
- Market Dynamics
- Market Segmentation, By Therapy Type
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2024 – 2034
- Y-o-Y Growth Analysis (%), 2024 – 2034
- Segment Trends
- Allogeneic Cell Therapy
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Autologous Cell Therapy
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Overview
- Market Segmentation, By Technology, 2024 – 2034, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2024 – 2034
- Y-o-Y Growth Analysis (%), 2024 – 2034
- Segment Trends
- Somatic Cell Technology
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Cell Immortalization Technology
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Viral Vector Technology
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Genome Editing Technology
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Cell Plasticity Technology
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- 3D Technology
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Overview
- Market Segmentation, By Source, 2024 – 2034, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2024 – 2034
- Y-o-Y Growth Analysis (%), 2024 – 2034
- Segment Trends
- IPSC’s
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Bone Marrow
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Umbilical Cord
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Adipose Tissue
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Neural Stem Cells
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Overview
- Market Segmentation, By Application, 2024 – 2034, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2024 – 2034
- Y-o-Y Growth Analysis (%), 2024 – 2034
- Segment Trends
- Musculoskeletal
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Cardiovascular
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Gastrointestinal
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Neurological
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Oncology
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Dermatology
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Others
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Overview
- Global Market, By Region, 2024 – 2034, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2024 – 2034
- Y-o-Y Growth Analysis (%), 2024 – 2034
- Regional Trends
- North America
- Market Size and Forecast (US$ Bn), By Therapy Type, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Technology, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Source, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Application, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Country, 2024 – 2034
- U.S.
- Canada
- Europe
- Market Size and Forecast (US$ Bn), By Therapy Type, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Technology, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Source, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Application, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Country, 2024 – 2034
- UK
- France
- Germany
- Russia
- Italy
- Rest of Europe
- Asia Pacific
- Market Size and Forecast (US$ Bn), By Therapy Type, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Technology, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Source, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Application, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Country, 2024 – 2034
- India
- Japan
- South Korea
- China
- Rest of Asia Pacific
- Overview
-
- Latin America
- Market Size and Forecast (US$ Bn), By Therapy Type, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Technology, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Source, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Application, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Country, 2024 – 2034
- Latin America
-
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- Market Size and Forecast (US$ Bn), By Therapy Type, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Technology, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Source, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Application, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Country, 2024 – 2034
-
-
-
- GCC
- Israel
- South Africa
- Rest of Middle East
-
-
- Competitive Landscape
- Heat Map Analysis
- Market Presence and Specificity Analysis
- Company Profiles
- Pharmicell Co. Ltd.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Merck Group
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Thermo Fisher Scientific Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Lonza Group
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Miltenyi Biotec GmBH
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Takara Bio Group
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- STEMCELL Technologies
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Cellular Dynamics International
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Becton Dickinson & Company
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Bio-Rad Laboratories, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- The Last Word
- Future Impact
- About Us
- Contact
FAQs
The Cell Therapy Manufacturing Market is segmented into Therapy Type, Technology, Source, Application and Region.
Cell Therapy Manufacturing Market is driven by factors like increasing inclination of physicians toward the therapeutic use of allogeneic therapies and increasing private and public investments in cell therapy industry.
By region, the Cell Therapy Manufacturing Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America market is estimated to witness a significantly high revenue share over the forecast period.
The key players operating the Cell Therapy Manufacturing Market includes, Pharmicell Co. Ltd., Merck Group, Thermo Fisher Scientific Inc., Lonza Group, Miltenyi Biotec GmBH, Takara Bio Group, STEMCELL Technologies, Cellular Dynamics International, Becton Dickinson & Company, Bio-Rad Laboratories, Inc., and others.
Cell Therapy Manufacturing Market was valued at US$ 4.7 Billion in 2024 and is projected to grow at a CAGR of 13.90% to reach US$ 17.3 Billion by 2034.